Fremanezumab for the Preventive Treatment of Chronic Migraine [PDF]
New England Journal of Medicine, 2017 BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine.
Stephen D Silberstein, Peter Goadsby
exaly +5 more sources
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial [PDF]
The Journal of Headache and Pain, 2021 Background The FOCUS study evaluated the efficacy of migraine preventive medications across different countries within the same patient population, particularly for patients with difficult-to-treat migraine. These prespecified subgroup analyses evaluated
Egilius L. H. Spierings +6 more
doaj +2 more sources
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States [PDF]
The Journal of Headache and Pain, 2021 Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness of fremanezumab are limited. This
Peter McAllister +9 more
doaj +3 more sources
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies [PDF]
The Journal of Headache and Pain, 2021 Background Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy.
Stephanie J. Nahas +9 more
doaj +2 more sources
Frontiers in Neurology, 2023 BackgroundThe effectiveness of fremanezumab in treating migraine has been demonstrated in randomized controlled trials. However, real-world study results are still limited.MethodsWe conducted a single-center, observational study that included patients ...
Keisuke Suzuki
exaly +3 more sources
Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study [PDF]
The Journal of Headache and PainObjective While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab.
Faisal Mohammad Amin +4 more
doaj +2 more sources
Semi-Automated Recording of Facial Sensitivity in Rat Demonstrates Antinociceptive Effects of the Anti-CGRP Antibody Fremanezumab [PDF]
Neurology International, 2023 Migraine pain is frequently accompanied by cranial hyperalgesia and allodynia. Calcitonin gene-related peptide (CGRP) is implicated in migraine pathophysiology but its role in facial hypersensitivity is not entirely clear.
Nicola Benedicter +6 more
doaj +3 more sources
A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy [PDF]
BMC NeurologyBackground Chronic migraine (CM) is the most severe and burdensome subtype of migraine. Fremanezumab is a monoclonal antibody that targets the calcitonin gene-related peptide pathway as a migraine preventive therapy.
Sharon Wolters +6 more
doaj +2 more sources
Journal of Headache and Pain, 2020 Background We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication overuse (MO).
Stephen D Silberstein +2 more
exaly +3 more sources
Long-term effectiveness of fremanezumab in episodic and chronic migraine patients in clinical routine – 24-months results from the prospective non-interventional FINESSE study [PDF]
The Journal of Headache and PainBackground The CGRP pathway targeting antibody fremanezumab is indicated for prevention of migraine in adults with ≥4 migraine days/month. To address the limited availability in real-world long-term data, the FINESSE study was initiated to provide real ...
Andreas Straube +6 more
doaj +2 more sources